ArticleRSC advances2025
Preparation of polysaccharide composite films using cyclodextrin-conjugated chitosan for sustained release of hydrophobic drugs.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclodextrin-conjugated polysaccharides are often used as functional materials for biological applications, such as drug carriers, because the hydrophobic cavity of the cyclodextrin moiety can encapsulate molecules. Herein, β-cyclodextrin (β-CD)-conjugated chitosan (CD-CHI) for loading and sustained-release of low-molecular-weight hydrophobic drugs was synthesized, and polysaccharide composite films containing β-CD units were prepared from polyion complexes consisting of chondroitin sulfate C and CD-CHI by hot press techniques. β-CD units of the obtained CD-CHI were modified by 9.2% of the amino groups in CHI units. The synthesized CD-CHI was used as a raw material for polysaccharide composite films. The mechanical strength and swelling ratio of the obtained films were comparable to those of films without β-CD. Furthermore, thiabendazole (TBZ) was loaded into the polysaccharide composite films, and it was suggested that the loaded TBZ formed inclusion complexes with the β-CD units in CD-CHI. The loaded TBZ showed sustained-release ability, and the release mechanism from the films was analyzed and described using two kinetic models. Based on these results, polysaccharide composite films using CD-CHI are expected to be used as sustained-release carriers for hydrophobic drugs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.